Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

Sen Miao; Gaoda Ju; Chonghua Jiang; Bing Xue; Lihua Zhao; Rui Zhang; Han Diao; Xingzhou Yu; Linlin Zhang; Xiaozao Pan; Hua Zhang; Lijuan Zang; Lei Wang; Tianhao Zhou

doi:10.3389/fmed.2023.1167676

Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

Front Med (Lausanne). 2023 Apr 4:10:1167676. doi: 10.3389/fmed.2023.1167676. eCollection 2023.

Authors

Sen Miao¹, Gaoda Ju², Chonghua Jiang³, Bing Xue¹, Lihua Zhao¹, Rui Zhang¹, Han Diao¹, Xingzhou Yu¹, Linlin Zhang¹, Xiaozao Pan¹, Hua Zhang¹, Lijuan Zang⁴, Lei Wang⁵, Tianhao Zhou⁶

Affiliations

¹ Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China.
² Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
³ Department of Neurosurgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China.
⁴ Department of Pathology Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
⁵ Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China.
⁶ Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Abstract

Background: Breast cancer (BC) is the most common malignant disease worldwide. Although the survival rate is improved in recent years, the prognosis is still bleak once recurrence and metastasis occur. It is vital to investigate more efficient biomarkers for predicting the metastasis and relapse of BC. DYNLT1 has been reported that participating in the progression of multiple cancers. However, there is still a lack of study about the correlation between DYNLT1 and BC.

Methods: In this study, we evaluated and validated the expression pattern and prognostic implication of DYNLT1 in BC with multiple public cohorts and BC tumor microarrays (TMAs) of paraffin-embedded tissues collected from the Affiliated Hospital of Jining Medical University. The response biomarkers for immune therapy, such as tumor mutational burden (TMB), between different DYNLT1 expression level BC samples were investigated using data from the TCGA-BRCA cohort utilizing public online tools. In addition, colony formation and transwell assay were conducted to verify the effects of DYNLT1 in BC cell line proliferation and invasion.

Results: The results demonstrated that DYNLT1 overexpressed in BC and predicted poor relapse-free survival in our own BC TMA cohort. In addition, DYNLT1 induced BC development by promoting MDA-MB-231 cell proliferation migration, and metastasis.

Conclusion: Altogether, our findings proposed that DYNLT1 could be a diagnostic and prognostic indicator in BC.

Keywords: DYNLT1; biomarker; breast cancer; immune checkpoint blocking therapy; prognosis.

Grants and funding

This study was funded by Lin He's Academician Workstation of New Medicine and Clinical Translation at Jining Medical University [JYHL2021 FMS08] and the Doctoral Research Fund of Affiliated Hospital of Jining Medical University [grant 2020-BS-007].